BPG is committed to discovery and dissemination of knowledge
Home / Archive / Volume 23, Issue 47
This Article
Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Supplementary Materials of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
  • Total Article Views (11456)
All Articles published online
The chart showing PDF series, WORD series, HTML series, Figures (1-6) series, Tables (1-1) series.
Item 
Count 
PDF1024
WORD330
HTML6332
Figures (1-6)255
Tables (1-1)218
 Sum=8159
Publishing Process of This Article
The chart showing Browse series, Download series.
Item 
Count 
Browse1275
Download2022
 Sum=3297
Dec 21, 2017 (publication date) through Dec 2, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Cited by in CrossRef
For: Kaji K, Takaya H, Saikawa S, Furukawa M, Sato S, Kawaratani H, Kitade M, Moriya K, Namisaki T, Akahane T, Mitoro A, Yoshiji H. Rifaximin ameliorates hepatic encephalopathy and endotoxemia without affecting the gut microbiome diversity. World J Gastroenterol 2017; 23(47): 8355-8366 [PMID: 29307995 DOI: 10.3748/wjg.v23.i47.8355]
URL: https://www.wjgnet.com/2150-5330/full/v23/i47/8355.htm
Number Citing Articles
1
Uta S. Koepf, Sebastian Scheidt, Gunnar T. R. Hischebeth, Christian P. Strassburg, Dieter C. Wirtz, Thomas M. Randau, Philipp Lutz. Increased rate of enteric bacteria as cause of periprosthetic joint infections in patients with liver cirrhosis. BMC Infectious Diseases 2022; 22(1) doi: 10.1186/s12879-022-07379-2
2
Zhen Yang, Lin Wang. Current, emerging, and potential therapies for non-alcoholic steatohepatitis. Frontiers in Pharmacology 2023; 14 doi: 10.3389/fphar.2023.1152042
3
Hiroaki Takaya, Tadashi Namisaki, Shinya Sato, Kosuke Kaji, Yuki Tsuji, Daisuke Kaya, Yukihisa Fujinaga, Yasuhiko Sawada, Naotaka Shimozato, Hideto Kawaratani, Kei Moriya, Takemi Akahane, Akira Mitoro, Hitoshi Yoshiji. Increased Endotoxin Activity Is Associated with the Risk of Developing Acute-on-Chronic Liver Failure. Journal of Clinical Medicine 2020; 9(5): 1467 doi: 10.3390/jcm9051467
4
Sung-Min Won, Ki Kwang Oh, Haripriya Gupta, Raja Ganesan, Satya Priya Sharma, Jin-Ju Jeong, Sang Jun Yoon, Min Kyo Jeong, Byeong Hyun Min, Ji Ye Hyun, Hee Jin Park, Jung A. Eom, Su Been Lee, Min Gi Cha, Goo Hyun Kwon, Mi Ran Choi, Dong Joon Kim, Ki Tae Suk. The Link between Gut Microbiota and Hepatic Encephalopathy. International Journal of Molecular Sciences 2022; 23(16): 8999 doi: 10.3390/ijms23168999
5
Haifeng Lu, Hua Zhang, Zhongwen Wu, Lanjuan Li. Microbiota-gut-liver-brain axis and hepatic encephalopathy. Microbiome Research Reports 2024; 3(2) doi: 10.20517/mrr.2023.44
6
Guihua Fang, Shuna Liu, Bin Liu. Preventive and therapeutic effects of rifaximin on hepatic encephalopathy with differential application dosages and strategies: a network meta-analysis. BMC Gastroenterology 2024; 24(1) doi: 10.1186/s12876-024-03184-0
7
Sandip Samanta, Debbie L. Shawcross. The Complex Interplay Between Gut-Brain, Gut-Liver, and Liver-Brain Axes. 2021; : 187 doi: 10.1016/B978-0-12-821927-0.00006-1
8
Ovidiu-Dumitru Ilie, Raluca Duta, Ilinca-Bianca Nita, Irina Dobrin, Irina-Luciana Gurzu, Irina Girleanu, Laura Huiban, Cristina Muzica, Alin Ciobica, Roxana Popescu, Petru Cianga, Carol Stanciu, Diana Cimpoesu, Anca Trifan. A Comprehensive Overview of the Past, Current, and Future Randomized Controlled Trials in Hepatic Encephalopathy. Medicina 2023; 59(12): 2143 doi: 10.3390/medicina59122143
9
Ryuta Kitagawa, Kazuyoshi Kon, Akira Uchiyama, Kumiko Arai, Shunhei Yamashina, Kyoko Kuwahara-Arai, Teruo Kirikae, Takashi Ueno, Kenichi Ikejima. Rifaximin prevents ethanol-induced liver injury in obese KK-Ay mice through modulation of small intestinal microbiota signature. American Journal of Physiology-Gastrointestinal and Liver Physiology 2019; 317(5): G707 doi: 10.1152/ajpgi.00372.2018
10
Yuki Fujimoto, Kosuke Kaji, Norihisa Nishimura, Masahide Enomoto, Koji Murata, Soichi Takeda, Hiroaki Takaya, Hideto Kawaratani, Kei Moriya, Tadashi Namisaki, Takemi Akahane, Hitoshi Yoshiji. Dual therapy with zinc acetate and rifaximin prevents from ethanol-induced liver fibrosis by maintaining intestinal barrier integrity. World Journal of Gastroenterology 2021; 27(48): 8323-8342 doi: 10.3748/wjg.v27.i48.8323
11
Akira Okada, Hayato Yamana, Satoko Yamaguchi, Kayo Ikeda Kurakawa, Nobuaki Michihata, Hiroki Matsui, Kiyohide Fushimi, Masaomi Nangaku, Toshimasa Yamauchi, Hideo Yasunaga, Takashi Kadowaki. Effect of Branched-Chain Amino Acid Infusion on In-Hospital Mortality of Patients With Hepatic Encephalopathy and End-Stage Kidney Disease: A Retrospective Cohort Study Using a National Inpatient Database. Journal of Renal Nutrition 2022; 32(4): 432 doi: 10.1053/j.jrn.2021.05.008
12
Koos de Wit, Ulrich Beuers, Anna Mukha, Edwin C. A. Stigter, M. Can Gulersonmez, Jose M. Ramos Pittol, Sabine Middendorp, R. Bart Takkenberg, Saskia W. C. van Mil. Rifaximin stimulates nitrogen detoxification by PXR‐independent mechanisms in human small intestinal organoids. Liver International 2023; 43(3): 649 doi: 10.1111/liv.15491
13
Jasmohan S. Bajaj, Alexander Khoruts. Microbiota changes and intestinal microbiota transplantation in liver diseases and cirrhosis. Journal of Hepatology 2020; 72(5): 1003 doi: 10.1016/j.jhep.2020.01.017
14
Xin-Yue Lv, Hui-Guo Ding, Jun-Fu Zheng, Chun-Lei Fan, Lei Li. Rifaximin improves survival in cirrhotic patients with refractory ascites: A real-world study. World Journal of Gastroenterology 2020; 26(2): 199-218 doi: 10.3748/wjg.v26.i2.199
15
Paola Leone, Gergana Mincheva, Tiziano Balzano, Michele Malaguarnera, Vicente Felipo, Marta Llansola. Rifaximin Improves Spatial Learning and Memory Impairment in Rats with Liver Damage-Associated Neuroinflammation. Biomedicines 2022; 10(6): 1263 doi: 10.3390/biomedicines10061263
16
M. Bartoletti, M. Rinaldi, Z. Pasquini, L. Scudeller, S. Piano, D.R. Giacobbe, A.E. Maraolo, L. Bussini, F. Del Puente, S. Incicco, P. Angeli, M. Giannella, M. Baldassarre, P. Caraceni, C. Campoli, M.C. Morelli, M. Cricca, S. Ambretti, I. Gentile, M. Bassetti, P. Viale. Risk factors for candidaemia in hospitalized patients with liver cirrhosis: a multicentre case–control–control study. Clinical Microbiology and Infection 2021; 27(2): 276 doi: 10.1016/j.cmi.2020.04.030
17
Masahide Enomoto, Kosuke Kaji, Norihisa Nishimura, Yuki Fujimoto, Koji Murata, Soichi Takeda, Yuki Tsuji, Yukihisa Fujinaga, Hiroaki Takaya, Hideto Kawaratani, Tadashi Namisaki, Takemi Akahane, Hitoshi Yoshiji. Rifaximin and lubiprostone mitigate liver fibrosis development by repairing gut barrier function in diet–induced rat steatohepatitis. Digestive and Liver Disease 2022; 54(10): 1392 doi: 10.1016/j.dld.2022.04.012
18
Nicholas C. Kortt, Cositha Santhakumar, Rebecca J. Davis, Simone I. Strasser, Geoffrey W. McCaughan, Ken Liu, Avik Majumdar. Prevalence and outcomes of Clostridioides difficile infection in liver transplant recipients. Transplant Infectious Disease 2022; 24(1) doi: 10.1111/tid.13758
19
Eric Kalo, Scott Read, Golo Ahlenstiel. Targeting Gut–Liver Axis for Treatment of Liver Fibrosis and Portal Hypertension. Livers 2021; 1(3): 147 doi: 10.3390/livers1030014
20
Mei‐Tong Nie, Pei‐Qin Wang, Pei‐Mei Shi, Xia‐Lu Hong, Xin Zhang, Baoyu Xiang, Menghui Zhang, Wei‐Fen Xie. Rifaximin treatment shapes a unique metagenome‐metabolism network in patients with decompensated cirrhosis. Journal of Gastroenterology and Hepatology 2024; 39(4): 762 doi: 10.1111/jgh.16484
21
Kenya Kamimura, Akira Sakamaki, Hiroteru Kamimura, Toru Setsu, Takeshi Yokoo, Masaaki Takamura, Shuji Terai. Considerations of elderly factors to manage the complication of liver cirrhosis in elderly patients. World Journal of Gastroenterology 2019; 25(15): 1817-1827 doi: 10.3748/wjg.v25.i15.1817
22
Daniela Campion, Ilaria Giovo, Paola Ponzo, Giorgio M Saracco, Federico Balzola, Carlo Alessandria. Dietary approach and gut microbiota modulation for chronic hepatic encephalopathy in cirrhosis. World Journal of Hepatology 2019; 11(6): 489-512 doi: 10.4254/wjh.v11.i6.489
23
Ezyana Effandie, Girish L. Gupte. Chronic Liver Disease – What’s New?. Indian Journal of Pediatrics 2024; 91(4): 391 doi: 10.1007/s12098-023-04819-y
24
Petra Zimmermann, Nigel Curtis. The effect of antibiotics on the composition of the intestinal microbiota - a systematic review. Journal of Infection 2019; 79(6): 471 doi: 10.1016/j.jinf.2019.10.008
25
Yoshimi Yukawa‐Muto, Tomonori Kamiya, Hideki Fujii, Hiroshi Mori, Atsushi Toyoda, Ikuya Sato, Yusuke Konishi, Akiyoshi Hirayama, Eiji Hara, Shinji Fukuda, Norifumi Kawada, Naoko Ohtani. Distinct responsiveness to rifaximin in patients with hepatic encephalopathy depends on functional gut microbial species. Hepatology Communications 2022; 6(8): 2090 doi: 10.1002/hep4.1954
26
Zefeng Chen, Jingsheng Ruan, Dinghua Li, Min Wang, Zhiwei Han, Wenxia Qiu, Guobin Wu. The Role of Intestinal Bacteria and Gut–Brain Axis in Hepatic Encephalopathy. Frontiers in Cellular and Infection Microbiology 2021; 10 doi: 10.3389/fcimb.2020.595759
27
Harry D Zacharias, Fady Kamel, Jaclyn Tan, Nina Kimer, Lise Lotte Gluud, Marsha Y Morgan. Rifaximin for prevention and treatment of hepatic encephalopathy in people with cirrhosis. Cochrane Database of Systematic Reviews 2023; 2023(7) doi: 10.1002/14651858.CD011585.pub2
28
Teresa C. Delgado, Javier de las Heras, María L. Martínez-Chantar. Understanding gut-liver axis nitrogen metabolism in Fatty Liver Disease. Frontiers in Endocrinology 2022; 13 doi: 10.3389/fendo.2022.1058101
29
Kazuhiko Ikeuchi, Takeya Tsutsumi, Aya Ishizaka, Taketoshi Mizutani, Ayako Sedohara, Michiko Koga, Satoru Tamaoki, Hiroshi Yotsuyanagi. Modulation of duodenal and jejunal microbiota by rifaximin in mice with CCl4-induced liver fibrosis. Gut Pathogens 2023; 15(1) doi: 10.1186/s13099-023-00541-4
30
Hideto Kawaratani, Yasuteru Kondo, Ryoji Tatsumi, Naoto Kawabe, Norikazu Tanabe, Akira Sakamaki, Kazuo Okumoto, Yoshihito Uchida, Kei Endo, Takumi Kawaguchi, Tsunekazu Oikawa, Yoji Ishizu, Shuhei Hige, Taro Takami, Shuji Terai, Yoshiyuki Ueno, Satoshi Mochida, Yasuhiro Takikawa, Takuji Torimura, Tomokazu Matsuura, Masatoshi Ishigami, Kazuhiko Koike, Hitoshi Yoshiji. Long-Term Efficacy and Safety of Rifaximin in Japanese Patients with Hepatic Encephalopathy: A Multicenter Retrospective Study. Journal of Clinical Medicine 2022; 11(6): 1571 doi: 10.3390/jcm11061571
31
Brian S Finlin, Beibei Zhu, Tania Boyechko, Philip M Westgate, Chee W Chia, Josephine M Egan, Philip A Kern. Effect of Rifaximin Treatment on Endotoxemia and Insulin Sensitivity in Humans. Journal of the Endocrine Society 2019; 3(9): 1641 doi: 10.1210/js.2019-00148
32
Kristien Nel Van Zyl, Siphiwe R. Matukane, Bianca L. Hamman, Andrew C. Whitelaw, Mae Newton-Foot. Effect of antibiotics on the human microbiome: a systematic review. International Journal of Antimicrobial Agents 2022; 59(2): 106502 doi: 10.1016/j.ijantimicag.2021.106502
33
Igor de Sousa Oliveira, Bárbara Prado de Albuquerque, Hugo Tomé de Souza Lima, Lara Bianca Soares Brandão, Lia Maki Hatisuka Imai, Mara Georgia de Sousa Lima, Mariana Presot Elias, Samanta Pereira Teodoro, Weverton Flôr Patrício, Gilberto Loiola de Vasconcelos. Tratamento e fatores preditivos de prognóstico do paciente com Encefalopatia Hepática (HE). Revista Científica Multidisciplinar Núcleo do Conhecimento 2020; : 95 doi: 10.32749/nucleodoconhecimento.com.br/saude/preditivos-de-prognostico
34
Yao Su, Xu-Pei Gan, Fei-Fei Li, Dong-Yao Zhang, Li Chen, Yan-Nan Cao, Hong-Hui Qiu, De-Cui Cheng, Jian-Fei Zu, Wen-Yu Liu, Hong-Kun Wang, Xian-Ming Xu. Effect of exposure to antibiotics on the gut microbiome and biochemical indexes of pregnant women. BMJ Open Diabetes Research & Care 2021; 9(2): e002321 doi: 10.1136/bmjdrc-2021-002321
35
Mitsuhiko Shibasaki, Takeshi Hatanaka, Yasushi Shimada, Tamon Nagashima, Masashi Namikawa, Shuichi Saito, Kenichi Hosonuma, Atsushi Naganuma, Daichi Takizawa, Hirotaka Arai, Takashi Kosone, Hitoshi Takagi, Ken Sato, Satoru Kakizaki, Toshio Uraoka. Efficacy and safety of rifaximin treatment in Japanese patients with hepatic encephalopathy. Kanzo 2020; 61(1): 1 doi: 10.2957/kanzo.61.1
36
Ryunosuke Noda, Giyoung Kwoun, Noriko Matsunaga, Takahiro Yoshikawa, Lisa Uchida, Takamoto Ohse. Rifaximin prevented the recurrence of hepatic encephalopathy in a hemodialysis patient ‒ A case report. Nihon Toseki Igakkai Zasshi 2021; 54(11): 591 doi: 10.4009/jsdt.54.591
37
Shinya Sato, Tadashi Namisaki, Koji Murata, Yuki Fujimoto, Soichi Takeda, Masahide Enomoto, Akihiko Shibamoto, Koji Ishida, Hiroyuki Ogawa, Hirotetsu Takagi, Yuki Tsuji, Daisuke Kaya, Yukihisa Fujinaga, Masanori Furukawa, Takashi Inoue, Yasuhiko Sawada, Norihisa Nishimura, Koh Kitagawa, Takahiro Ozutsumi, Hiroaki Takaya, Kosuke Kaji, Naotaka Shimozato, Hideto Kawaratani, Kei Moriya, Takemi Akahane, Akira Mitoro, Hitoshi Yoshiji. The association between sarcopenia and endotoxin in patients with alcoholic cirrhosis. Medicine 2021; 100(36): e27212 doi: 10.1097/MD.0000000000027212
38
Kunihiko Yokoyama, Akira Sakamaki, Kazuya Takahashi, Takumi Naruse, Chihiro Sato, Yuzo Kawata, Kentaro Tominaga, Hiroyuki Abe, Hiroki Sato, Atsunori Tsuchiya, Kenya Kamimura, Masaaki Takamura, Junji Yokoyama, Shuji Terai, Tatsuo Kanda. Hydrogen-producing small intestinal bacterial overgrowth is associated with hepatic encephalopathy and liver function. PLOS ONE 2022; 17(2): e0264459 doi: 10.1371/journal.pone.0264459
39
Stephen M. Riordan. Liver Diseases. 2020; : 695 doi: 10.1007/978-3-030-24432-3_64
40
Xiao Yu, Ye Jin, Wangxiao Zhou, Tingting Xiao, Zhongwen Wu, Junwei Su, Hainv Gao, Ping Shen, Beiwen Zheng, Qixia Luo, Lanjuan Li, Yonghong Xiao. Rifaximin Modulates the Gut Microbiota to Prevent Hepatic Encephalopathy in Liver Cirrhosis Without Impacting the Resistome. Frontiers in Cellular and Infection Microbiology 2022; 11 doi: 10.3389/fcimb.2021.761192
41
Keiji Yokoyama, Hiromi Fukuda, Ryo Yamauchi, Masashi Higashi, Takashi Miyayama, Tomotaka Higashi, Yotaro Uchida, Kumiko Shibata, Naoaki Tsuchiya, Atsushi Fukunaga, Kaoru Umeda, Kazuhide Takata, Takashi Tanaka, Satoshi Shakado, Shotaro Sakisaka, Fumihito Hirai. Long-Term Effects of Rifaximin on Patients with Hepatic Encephalopathy: Its Possible Effects on the Improvement in the Blood Ammonia Concentration Levels, Hepatic Spare Ability and Refractory Ascites. Medicina 2022; 58(9): 1276 doi: 10.3390/medicina58091276
42
皓月 田. The Application of Rifaximin in Patients with End Stage Liver Disease. Advances in Clinical Medicine 2024; 14(01): 466 doi: 10.12677/ACM.2024.141067
43
Marcus M. Mücke, Sabrina Rüschenbaum, Amelie Mayer, Victoria T. Mücke, Katharina M. Schwarzkopf, Stefan Zeuzem, Jan Kehrmann, René Scholtysik, Christian M. Lange. Stool and sputum microbiome during quinolone prophylaxis of spontaneous bacterial peritonitis: an exploratory study. Gut Pathogens 2020; 12(1) doi: 10.1186/s13099-020-00389-y
44
Guole Nie, Honglong Zhang, Danna Xie, Jun Yan, Xun Li. Liver cirrhosis and complications from the perspective of dysbiosis. Frontiers in Medicine 2024; 10 doi: 10.3389/fmed.2023.1320015
45
Yunyun Zhang, Shourong Lu, Ying Yang, Zhuo Wang, Bin Wang, Bingshan Zhang, Jie Yu, Wenwei Lu, Mingluo Pan, Jianxin Zhao, Shenghua Guo, Jin Cheng, Xiaorong Chen, Kan Hong, Gang Li, Zhiming Yu. The diversity of gut microbiota in type 2 diabetes with or without cognitive impairment. Aging Clinical and Experimental Research 2021; 33(3): 589 doi: 10.1007/s40520-020-01553-9
46
Hiroyuki Suzuki, Hitomi Sezaki, Fumitaka Suzuki, Kayoko Kasuya, Tomoya Sano, Shunichiro Fujiyama, Yusuke Kawamura, Tetsuya Hosaka, Norio Akuta, Satoshi Saitoh, Masahiro Kobayashi, Yasuji Arase, Kenji Ikeda, Yoshiyuki Suzuki, Hiromitsu Kumada. Real‐world effects of long‐term rifaximin treatment for Japanese patients with hepatic encephalopathy. Hepatology Research 2019; 49(12): 1406 doi: 10.1111/hepr.13415
47
Hiroki Nishikawa, Hirayuki Enomoto, Shuhei Nishiguchi, Hiroko Iijima. Sarcopenic Obesity in Liver Cirrhosis: Possible Mechanism and Clinical Impact. International Journal of Molecular Sciences 2021; 22(4): 1917 doi: 10.3390/ijms22041917
48
Divakar Dahiya, Poonam Singh Nigam. Antibiotic-Therapy-Induced Gut Dysbiosis Affecting Gut Microbiota—Brain Axis and Cognition: Restoration by Intake of Probiotics and Synbiotics. International Journal of Molecular Sciences 2023; 24(4): 3074 doi: 10.3390/ijms24043074
49
Kosuke Kaji, Soichiro Saikawa, Hiroaki Takaya, Yukihisa Fujinaga, Masanori Furukawa, Koh Kitagawa, Takahiro Ozutsumi, Daisuke Kaya, Yuki Tsuji, Yasuhiko Sawada, Hideto Kawaratani, Kei Moriya, Tadashi Namisaki, Takemi Akahane, Akira Mitoro, Hitoshi Yoshiji. Rifaximin Alleviates Endotoxemia with Decreased Serum Levels of Soluble CD163 and Mannose Receptor and Partial Modification of Gut Microbiota in Cirrhotic Patients. Antibiotics 2020; 9(4): 145 doi: 10.3390/antibiotics9040145
50
Penelope Hey, Marie Sinclair. Frailty and Sarcopenia in Cirrhosis. 2020; : 211 doi: 10.1007/978-3-030-26226-6_15
51
Yudai Fujiwara, Kazuyuki Suzuki, Kenji Yusa, Makoto Eizuka, Manami Miura, Yuki Watanabe, Hiroshi Takahashi, Yasuhiro Takikawa. Evaluation of the Long-term Administration of Rifaximin for More than Three Years in the Treatment of Repeated and Recurrent Overt Hepatic Encephalopathy. Internal Medicine 2021; 60(7): 1027 doi: 10.2169/internalmedicine.5793-20
52
Yasushi Okura, Tadashi Namisaki, Shinya Sato, Kei Moriya, Takemi Akahane, Mitsuteru Kitade, Hideto Kawaratani, Kosuke Kaji, Hiroaki Takaya, Yasuhiko Sawada, Naotaka Shimozato, Kenichiro Seki, Soichiro Saikawa, Keisuke Nakanishi, Masanori Furukawa, Yukihisa Fujinaga, Takuya Kubo, Daisuke Kaya, Yuki Tsuji, Takahiro Ozutsumi, Koh Kitagawa, Tsuyoshi Mashitani, Hiroyuki Ogawa, Koji Ishida, Akira Mitoro, Junichi Yamao, Hitoshi Yoshiji. Proton pump inhibitor therapy does not increase serum endotoxin activity in patients with cirrhosis. Hepatology Research 2019; 49(2): 232 doi: 10.1111/hepr.13249
53
Akira Sakamaki, Masaaki Takamura, Shuji Terai. The Evolving Landscape of Liver Cirrhosis Management. 2019; : 79 doi: 10.1007/978-981-13-7979-6_7
54
Antonio De Vincentis, Marco Santonico, Federica Del Chierico, Annamaria Altomare, Benedetta Marigliano, Alice Laudisio, Sofia Reddel, Simone Grasso, Alessandro Zompanti, Giorgio Pennazza, Lorenza Putignani, Michele Pier Luca Guarino, Michele Cicala, Raffaele Antonelli Incalzi. Gut Microbiota and Related Electronic Multisensorial System Changes in Subjects With Symptomatic Uncomplicated Diverticular Disease Undergoing Rifaximin Therapy. Frontiers in Medicine 2021; 8 doi: 10.3389/fmed.2021.655474
55
Ming Luo, Rui-Juan Xin, Fang-Rui Hu, Li Yao, Sheng-Juan Hu, Fei-Hu Bai. Role of gut microbiota in the pathogenesis and therapeutics of minimal hepatic encephalopathy <i>via </i>the gut-liver-brain axis. World Journal of Gastroenterology 2023; 29(1): 144-156 doi: 10.3748/wjg.v29.i1.144
56
Akira Okada, Hayato Yamana, Satoko Yamaguchi, Kayo Ikeda Kurakawa, Hiroki Matsui, Kiyohide Fushimi, Masaomi Nangaku, Takashi Kadowaki, Hideo Yasunaga. Outcomes of lactulose plus branched‐chain amino acid infusion and lactulose alone for hepatic encephalopathy: A retrospective cohort study using a national inpatient database. Hepatology Research 2020; 50(6): 693 doi: 10.1111/hepr.13486
57
Toshiki Horii, Sho Suzuki, Chika Takano, Hitoshi Shibuya, Ryoji Ichijima, Chika Kusano, Hisatomo Ikehara, Takuji Gotoda. Lower impact of vonoprazan–amoxicillin dual therapy on gut microbiota forHelicobacter pylorieradication. Journal of Gastroenterology and Hepatology 2021; 36(12): 3314 doi: 10.1111/jgh.15572
58
Lucia Giuli, Marta Maestri, Francesco Santopaolo, Maurizio Pompili, Francesca Romana Ponziani. Gut Microbiota and Neuroinflammation in Acute Liver Failure and Chronic Liver Disease. Metabolites 2023; 13(6): 772 doi: 10.3390/metabo13060772
59
João Vasques, Catarina Sousa Guerreiro, Joana Sousa, Mariana Pinto, Helena Cortez-Pinto. Nutritional support in cirrhotic patients with sarcopenia. Clinical Nutrition ESPEN 2019; 33: 12 doi: 10.1016/j.clnesp.2019.07.011
60
Patrick Lee, Brandon K. K. Fields, Tom Liang, Michael P. Dubé, Seth Politano, Haruki Komatsu. Veillonella Bacteremia in Alcoholic Hepatitis. Case Reports in Hepatology 2021; 2021: 1 doi: 10.1155/2021/9947213
61
Augusto Mantovani, Larisse Longo, Rutiane Ullmann Thoen, Pabulo Henrique Rampelotto, Raul Salinas, Gabriel Tayguara Silveira Guerreiro, Mário Reis Álvares-da-Silva. Firmicutes/Bacteroidetes and Firmicutes/Proteobacteria ratios are associated with worse prognosis in a cohort of Latin American patients with cirrhosis. Clinics 2024; 79: 100471 doi: 10.1016/j.clinsp.2024.100471
62
Jing Liu, Dakai Yang, Xiaojing Wang, Paul Tetteh Asare, Qingwen Zhang, Lixin Na, Lei Shao. Gut Microbiota Targeted Approach in the Management of Chronic Liver Diseases. Frontiers in Cellular and Infection Microbiology 2022; 12 doi: 10.3389/fcimb.2022.774335
63
Hitoshi Yoshiji, Tadashi Namisaki, Kosuke Kaji, Sven Francque. Portal Hypertension VII. 2022; : 221 doi: 10.1007/978-3-031-08552-9_19
64
Roman Maslennikov, Aliya Alieva, Elena Poluektova, Yury Zharikov, Andrey Suslov, Yana Letyagina, Ekaterina Vasileva, Anna Levshina, Evgenii Kozlov, Vladimir Ivashkin. Sarcopenia in cirrhosis: Prospects for therapy targeted to gut microbiota. World Journal of Gastroenterology 2023; 29(27): 4236-4251 doi: 10.3748/wjg.v29.i27.4236
65
Takumi Kawaguchi, Fumitaka Suzuki, Masatoshi Imamura, Naoya Murashima, Mikio Yanase, Tetsuya Mine, Masaki Fujisawa, Ikuya Sato, Hitoshi Yoshiji, Kiwamu Okita, Kazuyuki Suzuki. Rifaximin‐altered gut microbiota components associated with liver/neuropsychological functions in patients with hepatic encephalopathy: An exploratory data analysis of phase II/III clinical trials. Hepatology Research 2019; 49(4): 404 doi: 10.1111/hepr.13300
66
Hiroki Nishikawa, Hirayuki Enomoto, Shuhei Nishiguchi, Hiroko Iijima. Liver Cirrhosis and Sarcopenia from the Viewpoint of Dysbiosis. International Journal of Molecular Sciences 2020; 21(15): 5254 doi: 10.3390/ijms21155254
67
Bradley Reuter, Jasmohan S. Bajaj. Microbiome. Clinics in Liver Disease 2020; 24(3): 493 doi: 10.1016/j.cld.2020.04.006
68
Maren L. Smith, James B. Wade, Jennifer Wolstenholme, Jasmohan S. Bajaj. Gut microbiome-brain-cirrhosis axis. Hepatology 2024; 80(2): 465 doi: 10.1097/HEP.0000000000000344
69
Yukihisa Fujinaga, Hideto Kawaratani, Daisuke Kaya, Yuki Tsuji, Takahiro Ozutsumi, Masanori Furukawa, Koh Kitagawa, Shinya Sato, Norihisa Nishimura, Yasuhiko Sawada, Hiroaki Takaya, Kosuke Kaji, Naotaka Shimozato, Kei Moriya, Tadashi Namisaki, Takemi Akahane, Akira Mitoro, Hitoshi Yoshiji. Effective Combination Therapy of Angiotensin-II Receptor Blocker and Rifaximin for Hepatic Fibrosis in Rat Model of Nonalcoholic Steatohepatitis. International Journal of Molecular Sciences 2020; 21(15): 5589 doi: 10.3390/ijms21155589
70
Jasmohan S. Bajaj, Nita H. Salzman, Chathur Acharya, Richard K. Sterling, Melanie B. White, Edith A. Gavis, Andrew Fagan, Michael Hayward, Mary L. Holtz, Scott Matherly, Hannah Lee, Majdi Osman, Mohammad S. Siddiqui, Michael Fuchs, Puneet Puri, Masoumeh Sikaroodi, Patrick M. Gillevet. Fecal Microbial Transplant Capsules Are Safe in Hepatic Encephalopathy: A Phase 1, Randomized, Placebo‐Controlled Trial. Hepatology 2019; 70(5): 1690 doi: 10.1002/hep.30690
71
Md. Rezaul Karim, Safia Iqbal, Shahnawaz Mohammad, Jung Hyeok Lee, Daehyo Jung, Ramya Mathiyalagan, Deok-Chun Yang, Dong Uk Yang, Se Chan Kang. A review on Impact of dietary interventions, drugs, and traditional herbal supplements on the gut microbiome. Microbiological Research 2023; 271: 127346 doi: 10.1016/j.micres.2023.127346
72
Stephan Spahn, Daniel Roessler, Radu Pompilia, Gisela Gabernet, Beryl Primrose Gladstone, Marius Horger, Saskia Biskup, Magdalena Feldhahn, Sven Nahnsen, Franz J. Hilke, Bernhard Scheiner, Jean-François Dufour, Enrico N. De Toni, Matthias Pinter, Nisar P. Malek, Michael Bitzer. Clinical and Genetic Tumor Characteristics of Responding and Non-Responding Patients to PD-1 Inhibition in Hepatocellular Carcinoma. Cancers 2020; 12(12): 3830 doi: 10.3390/cancers12123830
73
Igor G. Bakulin, Inna A. Oganezova, Maria I. Skalinskaya, Ekaterina V. Skazyvaeva. Liver cirrosis and complication risk management. Terapevticheskii arkhiv 2021; 93(8): 963 doi: 10.26442/00403660.2021.08.200917
74
Narandalai Danshiitsoodol, Masafumi Noda, Keishi Kanno, Tomoyuki Uchida, Masanori Sugiyama. Plant-Derived Lactobacillus paracasei IJH-SONE68 Improves the Gut Microbiota Associated with Hepatic Disorders: A Randomized, Double-Blind, and Placebo-Controlled Clinical Trial. Nutrients 2022; 14(21): 4492 doi: 10.3390/nu14214492
75
Federica Di Vincenzo, Alberto Nicoletti, Marcantonio Negri, Federica Vitale, Lorenzo Zileri Dal Verme, Antonio Gasbarrini, Francesca Romana Ponziani, Lucia Cerrito. Gut Microbiota and Antibiotic Treatments for the Main Non-Oncologic Hepato-Biliary-Pancreatic Disorders. Antibiotics 2023; 12(6): 1068 doi: 10.3390/antibiotics12061068
76
Eric G Meissner. The Gut-Liver Axis in Hepatitis C Virus Infection: A Path Towards Altering the Natural History of Fibrosis Progression?. Clinical Infectious Diseases 2018; 67(6): 878 doi: 10.1093/cid/ciy208
77
Mazen Elsheikh, Ahmed El Sabagh, Islam B Mohamed, Megha Bhongade, Manal M Hassan, Prasun Kumar Jalal. Frailty in end-stage liver disease: Understanding pathophysiology, tools for assessment, and strategies for management. World Journal of Gastroenterology 2023; 29(46): 6028-6048 doi: 10.3748/wjg.v29.i46.6028
78
Tonatiuh Abimael Baltazar-Díaz, Verónica Riggen-Bueno, Donovan Brandon Cortina-Romero, Susana del Toro-Arreola, Jesse Haramati, Blanca Estela Bastidas-Ramírez, Miriam Ruth Bueno-Topete. Low-diversity microbiota and an increased metabolism of arginine and aromatic amino acids: a hallmark of hepatic encephalopathy in western Mexican patients with alcohol-associated cirrhosis. Journal of Applied Microbiology 2023; 134(6) doi: 10.1093/jambio/lxad113
Write to the Help Desk
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

California Corporate Number: 3537345